PLG regulates hnRNP-L expression in the rat striatum and pre-frontal cortex: Identification by ddPCR

Peptides

Volumn 24, Issue 1, 2003, Pages 137-146

  Costain, Willard J ^a   Mishra, Ram K ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; INTERMEDIN INHIBITING FACTOR;

AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DIFFERENTIAL DISPLAY; DOWN REGULATION; FRONTAL CORTEX; GENE CONTROL; MALE; MOLECULAR BIOLOGY; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; SEQUENCE HOMOLOGY; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CORPUS STRIATUM; DNA, COMPLEMENTARY; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEIN L; MALE; MOLECULAR SEQUENCE DATA; MSH RELEASE-INHIBITING HORMONE; POLYMERASE CHAIN REACTION; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; SEQUENCE HOMOLOGY, AMINO ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID;

ANIMALIA; MUS; MUS MUSCULUS; MUSCULUS;

EID: 0037255606     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(02)00286-3     Document Type: Article

References (42)

1. Baures P.W., Ojala W.H., Costain W.J., Ott M.C., Pradhan A., Gleason W.B.et al. Design, synthesis, and dopamine receptor modulating activity of diketopiperazine peptidomimetics of L-prolyl-L-leucylglycinamide. J. Med. Chem. 40(22):1997;3594-3600.
2. Baures P.W., Ojala W.H., Gleason W.B., Mishra R.K., Johnson R.L. Design, synthesis, X-ray analysis, and dopamine receptor-modulating activity of mimics of the "C5" hydrogen-bonded conformation in the peptidomimetic 2-oxo-3-(R)-[(2(S)-pyrrolidinylcarbonyl)amino]-1-pyrrolidineacetamide. J. Med. Chem. 37(22):1994;3677-3683.
3. 3H ]apomorphine binding sites Gen. Pharmacol. 14(6):1983;609-614.
4. Blaxall B.C., Pellett A.C., Wu S.C., Pende A., Port J.D. Purification and characterisation of β-adrenergic receptor mRNA-binding proteins. J. Biol. Chem. 275(6):2000;4290-4297.
5. Chiu P., Rajakumar G., Chiu S., Johnson R.L., Mishra R.K. Mesolimbic and striatal dopamine receptor supersensitivity: prophylactic and reveral effects of L-prolyl-L-leucyl-glycinamide (PLG). Peptides. 6(2):1985;179-183.
6. 3H ]spiroperidol binding in striatum of spontaneously hypertensive rat (SHR) Eur. J. Pharmacol. 82(3/4):1982;243-244.
7. Chiu S., Paulose C.S., Mishra R.K. Effect of L-prolyl-L-leucyl-blycinamide (PLG) on neuroleptic-induced catalepsy and dopamine/neuroleptic receptor binding. Peptides. 2(1):1981;105-111.
8. Chiu S., Paulose C.S., Mishra R.K. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide. Science. 214(4526):1981;1261-1262.
9. 3H -N-n-propylnorapomorphine to striatal membranes of rats: influence of prolyl-leucyl-glycinamide Pharmacology. 31(5):1985;241-247.
10. Ehrensing R.H., Kastin A.J., Wurzlow G.F., Michell G.F., Mebane A.H. Improvement in major depression after low subcutaneous doses of MIF-1. J. Affect. Disord. 31(4):1994;227-233.
11. Fielding P., Turnbull L., Prime W., Walshaw M., Field J.K. Heterogeneous nuclear ribonucleoprotein A2/B1 up-regulation in bronchial lavage specimens: a clinical marker of early lung cancer detection. Clin. Cancer Res. 5(12):1999;4048-4052.
12. Gaillard C., Cabannes E., Strauss F. Identity of the RNA-binding protein K of hnRNP particles with protein H16, a sequence-specific single strand DNA-binding protein. Nucleic Acids Res. 22(20):1994;4183-4186.
13. Garcia-Bassets I., Ortiz-Lombardia M., Pagans S., Romero A., Canals F., Avilés F.X., Azorín F. The identification of nuclear proteins that bind the homopyrimidine strand of d(GA.TC)n DNA sequences, but not the homopurine strand. Nucleic Acids Res. 27(16):1999;3267-3275.
14. Habelhah H., Shah K., Huang L., Ostareck-Lederer A., Burlingame A.L., Shokat K.M.et al. ERK phosphorylation drives cytoplasmic accumulation of hnRNP-K and inhibition of mRNA translation. Nat. Cell. Biol. 3(3):2001;325-330.
15. Hahm B., Kim Y.K., Kim J.H., Kim T.Y., Jang S.K. Heterogeneous nuclear ribonucleoprotein L interacts with the 3′ border of the internal ribosomal entry site of hepatitis C virus. J. Virol. 72(11):1998;8782-8788.
16. Hamilton B.J., Nichols R.C., Tsukamoto H., Boado R.J., Pardridge W.M., Rigby W.F. hnRNP A2 and hnRNP L bind the 3′UTR of glucose transporter 1 mRNA and exist as a complex in vivo. Biochem. Biophys. Res. Commun. 261(3):1999;646-651.
17. 2 analogues possessing cyclic amino acid residues at the C-terminal position. J. Med. Chem. 29(10):1986;2100-2104.
18. 2 analogues modified at the prolyl residue and evaluation of their effects on the receptor binding activity of the central dopamine receptor agonist ADTN. J. Med. Chem. 29(10):1986;2104-2107.
19. Kostrzewa R.M., Kastin A.J. Tyr-MIF-1 attenuates development of tolerance to spiperone-induced catalepsy in rats. Brain Res. Bull. 31(6):1993;707-712.
20. Kramer A. The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu. Rev. Biochem. 65:1996;367-409.
21. Kuninger D.T., Izumi T., Papaconstantinou J., Mitra S. Human AP-endonuclease 1 and hnRNP-L interact with a nCaRE-like repressor element in the AP-endonuclease 1 promoter. Nucleic Acids Res. 30(3):2002;823-829.
22. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227(259):1970;680-685.
23. Marcotte E.R., Chugh A., Barlas C., Mishra R.K. Differential regulation of striatal G protein levels following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration in C57 BL/6 mice. Neurosci. Lett. 306(1/2):2001;21-24.
24. Matsuyama S., Goto Y., Sueoka N., Ohkura Y., Tanaka Y., Nakachi K.et al. Heterogeneous nuclear ribonucleoprotein B1 expressed in esophageal squamous cell carcinomas as a new biomarker for diagnosis. Jpn. J. Cancer Res. 91(6):2000;658-663.
25. Michelotti E.F., Michelotti G.A., Aronsohn A.I., Levens D. Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene in vivo. Mol. Cell. Biol. 16(5):1996;2350-2360.
26. Mishra R.K., Chiu S., Chiu P., Mishra C.P. Pharmacology of L-prolyl-L-leucyl-glycinamide (PLG): a review. Methods Find. Exp. Clin. Pharmacol. 5(4):1983;203-233.
27. Mishra R.K., Srivastava L.K., Johnson R.L. Modulation of high-affinity CNS dopamine D2 receptor by L-pro-L-leu-glycinamide (PLG) analogue 3(R)-(N-L-prolylamino)-2-oxo-1-pyrrolidineacetamide. Prog. Neuropsychopharmacol. Biol. Psychiatr. 14(5):1990;821-827.
28. Mycroft F.J., Bhargava H.N., Wei E.T. Pharmacological activities of the MIF-1 analogues Pro-Leu-Gly-Tyr-Pro-Leu-Gly and pareptide. Peptides. 8(6):1987;1051-1055.
29. Ostrowski J., Van Seuningen I., Seger R., Rauch C.T., Sleath P.R., McMullen B.A.et al. Purification cloning, and expression of a murine phosphoprotein that binds the kappa B motif in vitro identifies it as the homolog of the human heterogeneous nuclear ribonucleoprotein K protein. Description of a novel DNA-dependent phosphorylation process. J. Biol. Chem. 269(26):1994;17626-17634.
30. Ott M.C., Costain W.J., Mishra R.K., Johnson R.L. L-Prolyl-L-leucyl-glycinamide and its peptidomimetic analog 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide (PAOPA) attenuate haloperidol-induced c-fos expression in the striatum. Peptides. 21(2):2000;301-308.
31. Piñol-Roma S., Swanson M.S., Gall J.G., Dreyfuss G. A novel heterogeneous nuclear RNP protein with a unique distribution on nascent transcripts. J. Cell. Biol. 109(6 (Pt 1)):1989;2575-2587.
32. Pollard A.J., Sparey C., Robson S.C., Krainer A.R., Europe-Finner G.N. Spatio-temporal expression of the trans-acting splicing factors SF2/ASF and heterogeneous ribonuclear proteins A1/A1B in the myometrium of the pregnant human uterus: a molecular mechanism for regulating regional protein isoform expression in vivo. J. Clin. Endocrinol. Metab. 85(5):2000;1928-1936.
33. Rajakumar G., Chiu P., Chiu S., Johnson R.L., Mishra R.K. 17-beta-Estradiol-induced increase in brain dopamine D-2 receptor: antagonism by MIF-1. Peptides. 8(6):1987;997-1002.
34. Rajakumar G., Naas F., Johnson R.L., Chiu S., Yu K.L., Mishra R.K. Down-regulation of haloperidol-induced striatal dopamine receptor supersensitivity by active analogues of L-prolyl-L-leucyl-glycinamide (PLG). Peptides. 8(5):1987;855-861.
35. Rajakumar G., Singh A.N., Naas F., Chiu S., Kwan C.Y., Johnson R.L.et al. L-Prolyl-L-leucyl-glycinamide analogues - a new class of peptide antihypertensives. J. Hypertens. Suppl. 4(5):1986;S106-S108.
36. Seeman P. Brain dopamine receptors. In: Creese I, Fraser CM, editors. Dopamine receptors, vol. 8. New York: A.R. Liss; 1987. p. 230-45.
37. Shih S.C., Claffey K.P. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J. Biol. Chem. 274(3):1999;1359-1365.
38. Srivastava L.K., Bajwa S.B., Johnson R.L., Mishra R.K. Interaction of L-prolyl-L-leucyl glycinamide with dopamine D2 receptor: evidence for modulation of agonist affinity states in bovine striatal membranes. J. Neurochem. 50(3):1988;960-968.
39. Takimoto M., Tomonaga T., Matunis M., Avigan M., Krutzsch H., Dreyfuss G.et al. Specific binding of heterogeneous ribonucleoprotein particle protein K to the human c-myc promoter in vitro. J. Biol. Chem. 268(24):1993;18249-18258.
40. Tomonaga T., Levens D. Heterogeneous nuclear ribonucleoprotein K is a DNA-binding transactivator. J. Biol. Chem. 270(9):1995;4875-4881.
41. Wang J., Dong Z., Bell L.R. Sex-lethal interactions with protein and RNA. Roles of glycine-rich and RNA binding domains. J. Biol. Chem. 272(35):1997;22227-22235.
42. Wilson M.E., Sonstegard T.S., Smith T.P., Fahrenkrug S.C., Ford S.P. Differential gene expression during elongation in the preimplantation pig embryo. Genesis. 26(1):2000;9-14.